Roche reports one-year Phase III vamikibart results in uveitic macular edema
Key highlights
- Phase III MEERKAT and SANDCAT showed sustained vision improvements through Week 52.
- Reductions in macular thickness persisted through Week 52 across both studies.
- About two-thirds of patients entering as‑needed dosing after Week 16 required no retreatment.
- Among patients who were retreated, the majority needed only one additional injection; safety remained consistent to Week 52.
Overview
Roche presented one-year data from the Phase III MEERKAT and SANDCAT studies of vamikibart in uveitic macular edema at the American Academy of Ophthalmology 2026 Annual Meeting, and issued a media release on October 10 detailing the results.
Efficacy at one year
Across both studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness through Week 52.
Dosing and retreatment
Patients entered an as‑needed dosing period after Week 16; approximately two-thirds required no retreatment, while the majority of those who did require retreatment received only one additional injection.
Safety
Vamikibart maintained a consistent safety profile through Week 52.
Source: Chugai Pharmaceutical